Related Experiment Video
Updated: Mar 25, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.8K
Levosimendan meta-analyses: Is there a pattern in the effect on mortality?
P Pollesello1, J Parissis2, M Kivikko1
1Critical Care Proprietary Products, Orion Pharma, Espoo, Finland.
International Journal of Cardiology
|February 17, 2016
Summary
Levosimendan significantly reduces patient mortality in various cardiac conditions, according to 25 meta-analyses. This inodilator demonstrates consistent benefits across diverse patient populations and therapeutic settings.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Levosimendan is an inodilator used for acute heart failure and other cardiac conditions.
- It has been investigated in diverse settings, including decompensated heart failure, cardiogenic shock, and post-surgery.
- Extensive data has been synthesized in 25 meta-analyses by international research groups.
Purpose of the Study:
- To review existing meta-analyses on levosimendan and identify common findings regarding patient mortality.
- To conduct a comparative meta-analysis of pivotal Phase II and III randomized controlled trials used for market approval.
Main Methods:
- Systematic review of 25 published meta-analyses on levosimendan.
- Comparative meta-analysis of six Phase II and III randomized double-blind trials.
- Analysis focused on patient mortality as a primary outcome.
Main Results:
- All meta-analyses consistently indicated reduced patient mortality with levosimendan.
- 22 out of 25 meta-analyses showed statistically significant benefits.
- Results were consistent across different clinical settings and comparators, aligning with the analysis of regulatory trial data.
Conclusions:
- Existing meta-analyses, encompassing over 6000 patients, demonstrate significant mortality benefits of levosimendan.
- The collective evidence strongly supports the efficacy and usefulness of levosimendan.
- Data from multiple randomized trials and meta-analyses confirm levosimendan's positive impact on patient survival.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:30Heart Failure V: Medical Management
512
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:26Heart Failure III: Clinical Manifestations
830
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
830